{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-033460","form_type":"8-K","ticker":"HSCS","cik":"0001468492","company_name":"HeartSciences Inc.","filed_at":"2023-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.012572+00:00","generated_at":"2026-06-13T06:21:18.786909+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"HeartSciences reports FY2023 progress; MyoVista pivotal study enrollment complete","bullets":["Completed patient enrollment for MyoVista wavECG pivotal study; FDA submission on track for later 2023.","Expanded IP portfolio to 40 granted patents, including US, Korean, and Israeli patents for AI ECG.","Entered multi-year AI ECG algorithm development collaboration with Rutgers University health system.","Cash and cash equivalents $1.7M as of April 30, 2023; no revenue (development-stage company).","AMA issued new Category III reimbursement codes for AI ECG risk assessment, validating market."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-033460","json":"https://secwatch.observer/filing/0000950170-23-033460.json","markdown":"https://secwatch.observer/filing/0000950170-23-033460.md","text":"https://secwatch.observer/filing/0000950170-23-033460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023033460/0000950170-23-033460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023033460/hscs-20230719.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:21:18.786909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26e489c51b663a7d2ba49dbea29799e1b1d1a15d","claim":"HeartSciences Inc. reported financial results for fiscal year ended April 30, 2023.","evidence_excerpt":"Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today provided a business update and reported financial results for the fiscal year ended April 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023033460/0000950170-23-033460-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended April 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}